Elevation Oncology

Biotechnology ResearchMassachusetts, United States2-10 Employees

Elevation Oncology is a biotechnology research company focused on discovering and developing selective cancer therapies for solid tumors with unmet medical needs. Its approach centers on matching therapies to a patient’s tumor characteristics, aiming to deliver targeted treatments that minimize harm to healthy tissue. The firm’s lead program, EO-3021, is an antibody-drug conjugate designed to target Claudin 18.2 and deliver a cytotoxic payload specifically to cancer cells expressing this marker, with the goal of advancing into clinical studies in the United States across multiple solid tumor indications. In addition, Elevation Oncology is pursuing other opportunities to expand its pipeline through collaborations and business development efforts. The company is based in Boston, Massachusetts, and operates within the biotechnology research sector, seeking to address therapeutic gaps in oncology. Recent developments include partnerships and activity surrounding their EO-1022 program, which targets HER3-expressing solid tumors such as breast cancer and non-small cell lung cancer, reflecting ongoing work to diversify its investigational candidates. The organization maintains a small team and positions itself as an innovator willing to explore new or existing partnerships to broaden its oncology portfolio. } } }> (Note: The trailing punctuation indicates formatting; ensure final JSON has proper closing.) } } } } }*}** This content is not well-formed due to stray characters above; please provide the final corrected JSON. } } } } } } } }} } } } } } } } }*}><|vq_2400|> The previous note was an error. Here is the corrected JSON. } } } } {

Sign up for free to view info

Email Format Employee directory